Related Experiment Video
Updated: Jul 13, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Effect of Resveratrol on Endothelial Function in Patients with CKD and Diabetes: A Randomized Controlled Trial
Colin J Gimblet1, Nicholas T Kruse2, Katharine Geasland3
1Department of Health and Human Physiology, The University of Iowa, Iowa City, Iowa.
Insights
Resveratrol supplementation improved endothelial function in patients with chronic kidney disease (CKD) and diabetes. This finding suggests a potential benefit for cardiovascular health in this high-risk population.
Area of Science:
- Cardiovascular Research
- Nephrology
- Endocrinology
Background:
- Patients with chronic kidney disease (CKD) and diabetes face elevated cardiovascular disease (CVD) risk due to impaired endothelial function.
- Resveratrol, a cardioprotective compound, may enhance endothelial function and reduce CVD burden in this population.
Purpose of the Study:
- To investigate the effects of resveratrol supplementation on endothelial function in patients with stage 3 CKD and diabetes.
Main Methods:
- A randomized, double-blind, placebo-controlled, crossover study involving 28 adults (84% men, aged 68±7 years) with stage 3 CKD and diabetes.
- Participants received 400 mg/d of resveratrol or placebo for 6 weeks.
- Endothelial function was assessed using brachial artery flow-mediated dilation (FMD).
Main Results:
- Resveratrol supplementation significantly increased flow-mediated dilation compared to placebo (ratio of geometric mean changes: 1.43; 95% CI: 1.15 to 1.77; P=0.001).
- No significant changes were observed in estimated glomerular filtration rate (eGFR), hemoglobin A1c, blood pressure, or nitroglycerin-mediated dilation.
- The improvement in FMD appeared independent of changes in traditional cardiovascular risk factors.
Conclusions:
- Resveratrol supplementation effectively improved endothelial function in individuals with both CKD and diabetes.
- These findings highlight resveratrol's potential as a therapeutic agent to mitigate cardiovascular risk in this vulnerable patient group.
Background:
Patients with CKD and diabetes are at higher risk of developing cardiovascular disease, in part, because of impaired endothelial function. Cardioprotective compounds such as resveratrol could improve endothelial function and attenuate the cardiovascular burden in patients with CKD and diabetes. We hypothesized that resveratrol supplementation would improve endothelial function in patients with CKD and diabetes.
Methods:
Twenty-eight adults aged 68±7 years (84% men) with stage 3 CKD and diabetes were enrolled in a randomized, double-blind, placebo-controlled, crossover study to investigate the effects of 6-week resveratrol supplementation (400 mg/d) on endothelial function. Endothelial function was determined through brachial artery flow-mediated dilation.
Results:
The mean values for eGFR and hemoglobin A 1c were 40±9 ml/min per 1.73 m 2 and 7.36%±0.72%, respectively. Compared with placebo, resveratrol supplementation increased flow-mediated dilation (ratio of geometric mean changes and 95% confidence interval for between-group comparisons, 1.43 (1.15 to 1.77); P value = 0.001). eGFR, hemoglobin A 1c , BP, and nitroglycerin-mediated dilation were unchanged with resveratrol or placebo ( P = 0.15), suggesting the observed change in flow-mediated dilation was likely independent of changes in traditional cardiovascular risk factors.
Conclusions:
Resveratrol supplementation improved endothelial function in patients with CKD and diabetes.
Clinical Trial Registry Name And Registration Number:
Resveratrol and Vascular Function in CKD, NCT03597568 .
Podcast:
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_20_CJN0000000000000337.mp3.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Kidney Transplant I: Introduction
Heart Failure Drugs: Diuretics
Chronic Kidney Disease IV: Nursing Management